Testosterone Undecanoate (Aqueous Suspension)
An unusual and rarely encountered presentation of testosterone undecanoate as a fine aqueous microcrystalline suspension rather than the standard castor-oil depot. The undecanoate ester and poor water solubility make a true aqueous suspension impractical, so most products sold under this description are either mislabelled oil solutions or crude micronised preparations with erratic release. Where genuine, it behaves as a long ester with slow, unpredictable absorption from the injection depot.
01 Overview
Testosterone undecanoate is the longest-chain testosterone ester in common use and is normally dissolved in castor oil (Nebido/Aveed) to give injections spaced 10-14 weeks apart. An aqueous suspension version is occasionally marketed by underground labs on the premise that removing the oil vehicle reduces injection volume irritation. In practice the extreme lipophilicity of the undecanoate ester resists aqueous suspension, absorption is inconsistent, and crystalline particles cause marked injection-site inflammation.
Because it is not a recognised pharmaceutical format, no clinical pharmacokinetic data exist for the aqueous form specifically. Users extrapolate from oil-based testosterone undecanoate, but release kinetics from a water suspension are faster and far more erratic, producing swinging serum testosterone rather than the smooth plateau the oil depot is designed for.
02 Mechanism
After intramuscular deposition the undecanoate ester is cleaved by tissue esterases to release free testosterone, which activates the androgen receptor in muscle and other tissues to increase protein synthesis and, via aromatisation, raises estradiol.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| TRT-equivalent | 100–200 mg/wk | IM | Extrapolated from oil-based TU; aqueous release is less predictable. |
| Enhancement | 250–500 mg/wk | IM | Split into frequent injections to buffer erratic release. |
Ester comparison
| Ester | Half-life | Injection freq. | Testosterone by mass |
|---|
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Increased lean body massTestosterone reliably increases muscle mass and strength dose-dependently; the ester only affects timing, not the underlying effect. | +3-6 kg over 12 weeks at supraphysiologic doses | Clinical | |
| Restored libido and wellbeingCorrecting low testosterone improves libido, mood and energy. | Normalisation in hypogonadal men | Clinical | |
| Injection-site inflammationCrystalline aqueous suspensions of long esters commonly provoke local swelling, redness and pain. | Frequent | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Estrogenic effects (gynecomastia, water retention)Aromatisation of testosterone to estradiol can cause breast tissue growth, fluid retention and raised blood pressure. | Moderate | Common at higher doses | Clinical | |
| Post-injection cough / oil embolism analogueLarge-volume or intravascular injection of suspensions can cause acute coughing and dyspnea. | Moderate | Uncommon | Anecdotal | |
| HPTA suppressionExogenous testosterone suppresses LH and FSH, shrinking the testes and halting spermatogenesis. | Severe | Universal at supraphysiologic doses | Clinical |